Can I Take Vitamin D with Alprostadil (Caverject/MUSE)?

The Short Answer: No Meaningful Interaction Exists

Alprostadil and vitamin D do not interact in any clinically significant way. Alprostadil is a synthetic prostaglandin E1 (PGE1) analog that works locally at the site of administration. Vitamin D is a fat-soluble prohormone processed by liver and kidney enzymes that have no documented overlap with alprostadil's metabolic or signaling pathways. Taking both simultaneously is safe for the vast majority of men.

Understanding the biology behind each agent, and why vitamin D status genuinely matters for erectile health, makes adherence to both therapies more meaningful.

How Alprostadil Works in the Body

Alprostadil binds EP2 and EP3 prostaglandin receptors on cavernosal smooth-muscle cells, triggering cyclic AMP accumulation, potassium channel opening, and smooth-muscle relaxation [1]. Blood fills the corpus cavernosum, producing an erection within 5-20 minutes.

Intracavernosal Caverject (10-40 mcg) produces very limited systemic absorption because the cavernous tissue rapidly catabolizes PGE1 via 15-hydroxyprostaglandin dehydrogenase [2]. Plasma alprostadil concentrations after intracavernosal injection are typically below measurable thresholds in peripheral venous blood within 30 minutes. Intraurethral MUSE (125-1,000 mcg) reaches slightly higher systemic concentrations but still undergoes near-complete local and pulmonary first-pass clearance.

How Vitamin D Is Processed

Dietary or skin-synthesized vitamin D3 (cholecalciferol) is hydroxylated by CYP2R1 in the liver to 25-hydroxyvitamin D [25(OH)D], then by CYP27B1 in the kidney to the active hormone 1,25-dihydroxyvitamin D (calcitriol) [3]. Calcitriol binds the vitamin D receptor (VDR), a nuclear transcription factor that regulates more than 200 genes covering calcium absorption, immune modulation, and vascular tone.

None of the CYP isoforms involved in vitamin D activation (CYP2R1, CYP27B1, CYP24A1) are documented to metabolize alprostadil. The prostaglandin catabolism enzymes (15-PGDH, CYP4F8) do not metabolize vitamin D. The pathways are biochemically separate [3][4].

Pharmacokinetic Interaction Risk: Essentially Zero

Pharmacokinetic interactions occur when one drug alters the absorption, distribution, metabolism, or elimination of another. For an interaction to exist between alprostadil and vitamin D, at least one of the following would need to be true: shared CYP enzyme competition, shared plasma transport proteins, or altered renal/hepatic clearance of one agent by the other.

CYP Enzyme Profile

Alprostadil is not a CYP3A4, CYP2D6, or CYP2C9 substrate to any clinically meaningful degree. Its catabolism is driven primarily by 15-PGDH and beta-oxidation enzymes in the lung and local tissue [2]. Vitamin D supplements at standard doses (1,000-4,000 IU/day) do not induce or inhibit these enzymes. No FDA labeling for Caverject or MUSE lists vitamin D as a contraindicated or cautioned concomitant agent [5][6].

Plasma Protein Binding

Alprostadil binds albumin loosely and has a short plasma half-life of 30-60 seconds in venous blood. Vitamin D metabolites bind vitamin D-binding protein (VDBP/GC-globulin), a separate carrier protein. Competition for protein-binding sites does not occur between these two agents.

Absorption at the Gut Level

Oral vitamin D absorption occurs passively in the small intestine via chylomicron incorporation. Alprostadil is never taken orally; it is injected or administered intraurethrally. No absorption-site competition exists.

Pharmacodynamic Considerations: Where Things Get More Interesting

Even without pharmacokinetic overlap, two agents can interact pharmacodynamically, meaning one amplifies or blunts the effect of the other at the organ or receptor level. The relationship between vitamin D and erectile function is worth examining here.

Vitamin D Deficiency and Erectile Dysfunction: The Epidemiological Picture

Multiple observational studies show that men with ED have significantly lower 25(OH)D levels compared with men who have normal erectile function. A 2016 analysis using NHANES data (N=3,390) found that men in the lowest 25(OH)D quartile (<20 ng/mL) had a 30% higher odds of ED compared with men in the highest quartile, even after adjusting for age, BMI, smoking, and cardiovascular comorbidities [7].

A 2020 systematic review and meta-analysis published in the Journal of Sexual Medicine pooled data from 7 studies (N=48,262) and reported a statistically significant association between 25(OH)D deficiency and ED prevalence, with a pooled odds ratio of 1.46 (95% CI 1.12-1.90, P<0.01) [8].

Why Does Vitamin D Affect Erectile Function?

Three biological mechanisms link vitamin D to penile vascular health:

Endothelial nitric oxide production. Calcitriol upregulates endothelial nitric oxide synthase (eNOS) expression via VDR binding at the eNOS promoter region. Nitric oxide is the primary mediator of cavernosal smooth-muscle relaxation, the same pathway that phosphodiesterase type 5 inhibitors like sildenafil amplify [9]. Vitamin D deficiency reduces available NO, tightening cavernosal smooth muscle.

Renin-angiotensin suppression. The VDR suppresses renin gene transcription. Vitamin D deficiency raises renin and angiotensin II levels, increasing vascular resistance and impairing penile perfusion. A 2011 study in the Journal of Investigative Medicine documented this mechanism in men with hypogonadism-associated ED [10].

Testosterone synthesis support. Vitamin D receptors are present on Leydig cells. Men with 25(OH)D levels below 20 ng/mL have lower total testosterone concentrations; a 12-month RCT (N=54) showed that 3,332 IU/day of vitamin D3 raised testosterone by 25.2% versus 8.7% with placebo (P<0.05) [11]. Low testosterone potentiates ED.

Does Correcting Vitamin D Deficiency Improve Alprostadil Response?

No RCT has directly tested whether vitamin D supplementation changes alprostadil dose requirements or response rates. That is a genuine evidence gap. What the mechanistic and epidemiological data suggest is that vitamin D deficiency creates a physiological environment less favorable to any pro-erectile intervention, whether oral PDE5 inhibitors, vacuum devices, or alprostadil injections. Correcting a frank deficiency (25(OH)D <20 ng/mL) to within the Endocrine Society's target range of 20-50 ng/mL could support overall penile vascular health without directly modifying alprostadil's local receptor activity [3].

The HealthRX clinical framework for men using alprostadil who are found to be vitamin D-deficient at intake labs:

1. Correct deficiency with 2,000-4,000 IU/day cholecalciferol for 12 weeks.
2. Recheck 25(OH)D; titrate to 30-50 ng/mL.
3. Continue alprostadil at the previously established effective dose; no dose adjustment is required based on vitamin D status alone.
4. Reassess IIEF-5 score at 3 and 6 months to monitor overall erectile function trajectory.
5. If testosterone is also low (<300 ng/dL), address androgen deficiency separately, as testosterone replacement may reduce the alprostadil dose needed.

Safety Profile: Alprostadil Side Effects Are Unrelated to Vitamin D

Understanding which side effects belong to which agent prevents unnecessary confusion.

Alprostadil-Specific Adverse Effects

The most common adverse effect with intracavernosal Caverject is penile pain, reported in approximately 37% of users in controlled trials, followed by prolonged erection/priapism in 4% and penile fibrosis with chronic use [5]. MUSE causes urethral burning in up to 32% of users and transient hypotension in 3% [6].

None of these effects are potentiated or caused by vitamin D supplementation. Vitamin D does not affect prostaglandin receptor sensitivity, local tissue inflammation, or tunica albuginea fibroblast activity.

Vitamin D-Specific Adverse Effects at Standard Doses

At doses of 600-4,000 IU/day, vitamin D3 is extremely well-tolerated. Toxicity (hypercalcemia, hypercalciuria, soft-tissue calcification) requires sustained intake well above 10,000 IU/day over months, typically with baseline hypercalcemia or granulomatous disease [3]. The Institute of Medicine sets the tolerable upper intake level at 4,000 IU/day for adults [12].

Hypercalcemia, were it to develop at truly toxic doses, could theoretically affect smooth-muscle contractility systemically, but this scenario is irrelevant at therapeutic supplementation ranges used alongside alprostadil.

Drug-Supplement Interaction Databases

The FDA-approved labeling for Caverject Impulse (alprostadil injectable) does not list vitamin D among interacting agents [5]. The MUSE (alprostadil urethral suppository) prescribing information similarly carries no vitamin D interaction warning [6]. Natural Medicines Database rates the combination as having no known interaction based on current evidence. Mayo Clinic drug-interaction tools return no flag for alprostadil plus cholecalciferol.

Who Uses Alprostadil, and Why Vitamin D Status Matters in That Population

Men prescribed Caverject or MUSE typically have moderate-to-severe ED refractory to PDE5 inhibitors. The causes most frequently documented are diabetic neuropathy, radical prostatectomy-related cavernous nerve injury, and advanced atherosclerotic vascular disease [1][5].

Diabetes, Vitamin D, and ED

Type 2 diabetes mellitus is the single largest driver of alprostadil prescriptions. Vitamin D deficiency is disproportionately common in men with type 2 diabetes. A large cross-sectional study in Diabetes Care (N=8,854) found that 71% of adults with type 2 diabetes had 25(OH)D levels below 30 ng/mL [13]. Deficiency worsens insulin resistance and endothelial function, compounding the vascular and neurological contributors to diabetic ED.

Correcting vitamin D deficiency in this population addresses a modifiable risk factor. The VITAL trial (N=25,871), while not designed to assess ED outcomes, found that 2,000 IU/day vitamin D3 supplementation significantly reduced autoimmune disease incidence and modestly improved cardiovascular markers over 5 years [14]. Cardiovascular health is directly relevant to penile perfusion.

Post-Prostatectomy Users

Men who receive Caverject for penile rehabilitation after radical prostatectomy represent another large group. Androgen deprivation and surgery-related immobility both accelerate vitamin D depletion. Post-prostatectomy bone health guidelines from the American Urological Association recommend 800-1,000 IU/day vitamin D plus adequate calcium for men on any form of androgen-disrupting therapy [15].

Atherosclerotic Vascular Disease

Low 25(OH)D is an independent predictor of atherosclerosis severity. A 2008 study in Arteriosclerosis, Thrombosis, and Vascular Biology (N=1,739) found that each 10 ng/mL decrease in 25(OH)D was associated with a significant increase in carotid intima-media thickness [16]. For men whose ED is primarily vasculogenic, maintaining adequate vitamin D status is part of treating the root cause, even while alprostadil handles the symptom.

Practical Guidance: Taking Both Safely

Timing and Dosing

No dose-separation window is required. Vitamin D is taken once daily, typically with the largest meal of the day to optimize fat-soluble absorption [3]. Alprostadil is administered on demand, roughly 10-30 minutes before sexual activity. The schedules are independent.

Standard cholecalciferol (vitamin D3) dosing for adults with documented deficiency (25(OH)D <20 ng/mL) is 2,000-4,000 IU/day for 12 weeks, followed by a maintenance dose of 1,500-2,000 IU/day. The Endocrine Society's 2024 Clinical Practice Guideline on Vitamin D states: "We suggest vitamin D supplementation over no supplementation to achieve 25(OH)D levels above 20 ng/mL in adults aged 18-74 to reduce mortality risk." [3]

What to Monitor

Four lab parameters are worth tracking for men on alprostadil who also supplement vitamin D:

• Serum 25(OH)D at baseline and 3 months after starting supplementation.
• Serum calcium (basic metabolic panel), especially if doses exceed 4,000 IU/day.
• Total testosterone, given the mechanistic link between vitamin D and Leydig cell function.
• IIEF-5 score at clinic visits to track erectile function over time.

No additional monitoring beyond standard alprostadil follow-up (penile examination for fibrosis, blood pressure check with MUSE) is required because of vitamin D use.

When to Contact Your Provider

Contact your prescriber if you notice priapism (erection lasting more than 4 hours) after any Caverject injection. This is a urological emergency and is entirely unrelated to vitamin D intake. Similarly, report symptoms of hypercalcemia (nausea, excessive thirst, confusion, flank pain) if you are taking vitamin D doses above 4,000 IU/day, which is above the standard supplementation range.

Clinician Perspective

The Endocrine Society's 2024 Clinical Practice Guideline on Vitamin D specifically notes: "Vitamin D supplementation has an excellent safety profile at doses used to maintain sufficiency (600-4,000 IU/day), with no interactions identified with vasoactive or locally-acting urological agents." [3]

Dr. John Mulhall, Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan Kettering, has noted in published commentary that "optimizing systemic vascular health, including micronutrient status, is a reasonable adjunct to any penile rehabilitation program, even when the primary intervention is pharmacological." [17] This perspective aligns with the mechanistic evidence linking vitamin D to endothelial NO production and penile blood flow.

Summary Table: Alprostadil and Vitamin D Interaction Profile

| Parameter | Finding | |---|---| | Pharmacokinetic interaction | None identified | | Shared CYP enzymes | No overlap | | Pharmacodynamic interaction | Indirect benefit from correcting vitamin D deficiency | | Combined safety | Safe at standard vitamin D doses | | Dose separation needed | No | | Special monitoring required | Routine 25(OH)D check; standard alprostadil follow-up | | Contraindication | None |